JPWO2022051304A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022051304A5
JPWO2022051304A5 JP2023537886A JP2023537886A JPWO2022051304A5 JP WO2022051304 A5 JPWO2022051304 A5 JP WO2022051304A5 JP 2023537886 A JP2023537886 A JP 2023537886A JP 2023537886 A JP2023537886 A JP 2023537886A JP WO2022051304 A5 JPWO2022051304 A5 JP WO2022051304A5
Authority
JP
Japan
Prior art keywords
acid
composition
choline
ionic liquid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539699A (ja
JP2023539699A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048537 external-priority patent/WO2022051304A1/en
Publication of JP2023539699A publication Critical patent/JP2023539699A/ja
Publication of JPWO2022051304A5 publication Critical patent/JPWO2022051304A5/ja
Publication of JP2023539699A5 publication Critical patent/JP2023539699A5/ja
Pending legal-status Critical Current

Links

JP2023537886A 2020-09-01 2021-08-31 糖尿病を治療するためのイオン性液体製剤 Pending JP2023539699A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063073172P 2020-09-01 2020-09-01
US63/073,172 2020-09-01
US202163154461P 2021-02-26 2021-02-26
US63/154,461 2021-02-26
US202163160575P 2021-03-12 2021-03-12
US63/160,575 2021-03-12
PCT/US2021/048537 WO2022051304A1 (en) 2020-09-01 2021-08-31 Ionic liquid formulations for treating diabetes

Publications (3)

Publication Number Publication Date
JP2023539699A JP2023539699A (ja) 2023-09-15
JPWO2022051304A5 true JPWO2022051304A5 (https=) 2025-05-01
JP2023539699A5 JP2023539699A5 (https=) 2025-05-01

Family

ID=80491938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537886A Pending JP2023539699A (ja) 2020-09-01 2021-08-31 糖尿病を治療するためのイオン性液体製剤

Country Status (9)

Country Link
US (1) US20240130994A1 (https=)
EP (1) EP4208160A4 (https=)
JP (1) JP2023539699A (https=)
KR (1) KR20230098144A (https=)
AU (1) AU2021336289A1 (https=)
CA (1) CA3191276A1 (https=)
IL (1) IL301024A (https=)
MX (1) MX2023002510A (https=)
WO (1) WO2022051304A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
WO2025264979A1 (en) * 2024-06-21 2025-12-26 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of dual glp-1/amylin receptor agonists and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1886677A1 (en) * 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
AU2015249035A1 (en) * 2014-11-14 2016-06-02 Zoran Ivanov Compositions and methods for treatment or prophylaxis of a liver condition
US20160177222A1 (en) * 2014-12-19 2016-06-23 The Procter & Gamble Company Ionic liquid systems
CN111918644A (zh) * 2017-11-17 2020-11-10 哈佛大学校长及研究员协会 用于内部递送的离子液体
EP3768240A4 (en) * 2018-03-19 2021-12-22 Cage Bio Inc. COMPOSITIONS OF IONIC LIQUID FOR THE TREATMENT OF ROSACEA
US20220257767A1 (en) * 2019-04-03 2022-08-18 President And Fellows Of Harvard College Ionic liquids for drug delivery
JP2024518169A (ja) * 2021-05-05 2024-04-25 アイ2オー セラピューティクス,インク. 炎症性疾患および自己免疫疾患を処置するためのイオン性液体製剤
WO2023286120A1 (ja) * 2021-07-12 2023-01-19 国立大学法人九州大学 経皮吸収剤

Similar Documents

Publication Publication Date Title
US12233110B2 (en) Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof
AU2018381124B2 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
TWI250163B (en) Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US20150258052A1 (en) Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
HUP0400645A2 (hu) NMDA-receptor agonistát tartalmazó gyógyászati készítmények
NZ551196A (en) Compounds and compositions for delivering active agents
JP7062846B1 (ja) 安定な医薬組成物
US20240130994A1 (en) Ionic liquid formulations for treating diabetes
JPWO2022051304A5 (https=)
WO1994000417A1 (fr) Compose a base de tranexamate de zinc
JPWO2020205409A5 (https=)
JP7549593B2 (ja) Glp-1ペプチドを噴霧乾燥するためのプロセス
JP2009542589A (ja) 4−[((4−カルボキシブチル)−{2−[(4−フェネチルベンジル)オキシ]−フェネチル}アミノ)メチル]安息香酸の水性医薬製剤
JPWO2023086499A5 (https=)
CN116635023A (zh) 用于治疗糖尿病的离子液体制剂
US20240245617A1 (en) Lipid-based topical injection formulations
WO2025141472A1 (en) Stable pharmaceutical compositions comprising tirzepatide
JP2004099493A (ja) 4−[6−[n−イソブチル−n−(4−メチル−2−チアゾリルスルフォニル)アミノ]インダン−5−イルオキシメチル]安息香酸の新規結晶、その製造方法およびそれを有効成分として含有する薬剤
EP2053918A2 (en) Synthesis of propyl phenoxy ethers and use as delivery agents
EA051057B1 (ru) Составы ионных жидкостей для лечения диабета
JPWO2023059846A5 (https=)
JPS60252410A (ja) 徐放性経鼻用製剤およびその使用方法
JPH0376302B2 (https=)